



February 20, 2015

---

---

## SENATE BILL No. 93

---

DIGEST OF SB 93 (Updated February 18, 2015 1:44 pm - DI 106)

**Citations Affected:** IC 4-22; IC 25-26; IC 35-31.5.

**Synopsis:** Synthetic drugs. Requires the publisher of the Indiana administrative code to publish a list of substances declared by the board of pharmacy to be synthetic drugs in a specific location in the Indiana administrative code, and requires the board of pharmacy to include a link to that provision of the Indiana administrative code on its Internet web site.

**Effective:** Upon passage.

---

---

### Merritt, Head

---

---

January 6, 2015, read first time and referred to Committee on Rules & Legislative Procedure.

February 10, 2015, amended; reassigned to Committee on Judiciary.

February 19, 2015, amended, reported favorably — Do Pass.

---

---

SB 93—LS 6185/DI 13





February 20, 2015

First Regular Session 119th General Assembly (2015)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2014 Regular Session and 2014 Second Regular Technical Session of the General Assembly.

## SENATE BILL No. 93

---

A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

*Be it enacted by the General Assembly of the State of Indiana:*

1 SECTION 1. IC 4-22-2-37.2, IS ADDED TO THE INDIANA  
2 CODE AS A **NEW** SECTION TO READ AS FOLLOWS  
3 [EFFECTIVE UPON PASSAGE]: **Sec. 37.2. (a) This section applies**  
4 **to a rule (including an emergency rule under IC 25-26-13-4.1)**  
5 **adopted by the Indiana board of pharmacy declaring a substance**  
6 **to be a synthetic drug.**

7 (b) The publisher of the Indiana administrative code shall  
8 establish a new article in the Indiana administrative code with the  
9 citation 856 IAC 8 and entitled "SYNTHETIC DRUGS". The  
10 article must be in the format of the Indiana administrative code.

11 (c) Not later than thirty (30) days after the publisher of the  
12 Indiana administrative code receives for filing a rule (including an  
13 emergency rule under IC 25-26-13-4.1) adopted by the Indiana  
14 board of pharmacy declaring a substance to be a synthetic drug,  
15 the publisher shall publish the name of the synthetic drug in 856  
16 IAC 8, in the format of the Indiana administrative code.

SB 93—LS 6185/DI 13



1 (d) Before July 1, 2015, the publisher of the Indiana  
 2 administrative code shall collect and compile a list of all substances  
 3 previously declared by the Indiana board of pharmacy to be  
 4 synthetic drugs by rule and published in the Indiana Register. The  
 5 publisher shall publish the list of these drugs in 856 IAC 8, unless  
 6 the rule declaring the substances to be synthetic drugs has expired  
 7 and has not been readopted.

8 (e) If the publisher of the Indiana administrative code receives  
 9 notice from the Indiana board of pharmacy that a rule declaring  
 10 a compound to be a synthetic drug has expired and has not been  
 11 readopted, the publisher shall remove that compound from the list  
 12 of synthetic drugs in 856 IAC 8.

13 SECTION 2. IC 25-26-13-4.1, AS AMENDED BY P.L.196-2013,  
 14 SECTION 11, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 15 UPON PASSAGE]: Sec. 4.1. (a) The board may adopt an emergency  
 16 rule to declare that a substance is a synthetic drug.

17 (b) The board may, on its own initiative or under a written request  
 18 from the state police department, the United States Drug Enforcement  
 19 Administration, or a poison control center, adopt an emergency rule  
 20 declaring a substance to be a synthetic drug if the board finds that the  
 21 substance:

- 22 (1) has been scheduled or emergency scheduled by the United  
 23 States Drug Enforcement Administration;
- 24 (2) has been scheduled, emergency scheduled, or criminalized by  
 25 another state; or
- 26 (3) has:
  - 27 (A) a high potential for abuse; and
  - 28 (B) no accepted medical use in treatment in the United States  
 29 or lacks accepted safety for use in treatment under medical  
 30 supervision.

31 (c) In making its determination under subsection (b)(3), the board  
 32 shall consider the following factors relating to the substance:

- 33 (1) The actual or relative potential for abuse.
- 34 (2) Scientific evidence of the substance's pharmacological effect,  
 35 if known.
- 36 (3) The state of current scientific knowledge regarding the  
 37 substance.
- 38 (4) The history and current pattern of abuse of the substance.
- 39 (5) The scope, duration, and significance of abuse of the  
 40 substance.
- 41 (6) The degree of risk to the public health.
- 42 (7) The psychic or psychological dependence liability of the



1 substance.

2 (d) A rule adopted under this section becomes effective thirty (30)  
3 days after it is filed with the publisher under IC 4-22-2-37.1.

4 (e) A rule adopted under this section expires on June 30 of the year  
5 following the year in which it is filed with the publisher under  
6 IC 4-22-2-37.1. **A rule adopted under this section must include the**  
7 **date on which the rule expires.**

8 (f) The board may readopt under this section an emergency rule that  
9 has expired.

10 **(g) An emergency rule adopted by the board under this section**  
11 **expires on the earlier of the following dates:**

12 **(1) The expiration date described in subsection (e).**

13 **(2) The date the emergency rule is amended or repealed by a**  
14 **later rule adopted under this section.**

15 **(h) The board shall include a prominent link on the home page**  
16 **of its Internet web site to the list of synthetic drugs in 856 IAC 8**  
17 **maintained by the publisher of the Indiana administrative code.**

18 SECTION 3. IC 35-31.5-2-321, AS AMENDED BY P.L.196-2013,  
19 SECTION 16, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
20 UPON PASSAGE]: Sec. 321. "Synthetic drug" means:

21 (1) a substance containing one (1) or more of the following  
22 chemical compounds, including an analog of the compound:

23 (A) JWH-015 ((2-Methyl-1-propyl-1H-  
24 indol-3-yl)-1-naphthalenylmethanone).

25 (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).

26 (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).

27 (D) JWH-073

28 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).

29 (E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol-  
30 3-yl)methanone).

31 (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).

32 (G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)-  
33 naphthalen-1-yl-methanone).

34 (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).

35 (I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).

36 (J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).

37 (K) HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl-  
38 3-(2-methyloctan-2-yl)-

39 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).

40 (L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl-  
41 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo

42 [c]chromen-1-ol).



- 1 (M) HU-308 [(1R,2R,5R)-2-[2,6-dimethoxy-4-  
2 (2-methyloctan-2-yl)phenyl]-  
3 7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
- 4 (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6-  
5 (1-methylethenyl)-2-cyclohexen-1-yl]-5  
6 -pentyl-2,5-cyclohexadiene-1,4-dione).
- 7 (O) CP 55,940  
8 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-  
9 5-(2-methyloctan-2-yl)phenol).
- 10 (P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5-  
11 (2-methyloctan-2-yl)phenol) and its homologues, or  
12 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)  
13 phenol), where side chain n=5, and homologues where side  
14 chain n=4, 6, or 7.
- 15 (Q) WIN 55212-2  
16 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)  
17 pyrrolo [1,2,3-de)- 1,4- benzoxazin-  
18 6-yl]-1-naphthalenylmethanone).
- 19 (R) RCS-4 ((4-methoxyphenyl)  
20 (1-pentyl-1H-indol-3-yl)methanone).
- 21 (S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H-  
22 indol-3-yl)-2-(2-methoxyphenyl)ethanone).
- 23 (T) 4-Methylmethcathinone. Other name: mephedrone.
- 24 (U) 3,4-Methylenedioxymethcathinone. Other name:  
25 methylone.
- 26 (V) Fluoromethcathinone.
- 27 (W) 4-Methoxymethcathinone. Other name: methedrone.
- 28 (X) 4-Ethylmethcathinone (4-EMC).
- 29 (Y) Methylenedioxyprovalerone. Other name: MDPV.
- 30 (Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
- 31 (AA) JWH-098, or  
32 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
- 33 (BB) JWH-164, or  
34 1-pentyl-3-(7-methoxy-1-naphthoyl)indole.
- 35 (CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.
- 36 (DD) JWH-201, or  
37 1-pentyl-3-(4-methoxyphenylacetyl)indole.
- 38 (EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
- 39 (FF) AM-694, or  
40 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
- 41 (GG) CP 50,556-1, or  
42 [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylp



1	ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1
2	-yl] acetate.
3	(HH) Dimethylheptylpyran, or DMHP.
4	(II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
5	(JJ) 6-APB [6-(2-aminopropyl)benzofuran].
6	(LL) 7-hydroxymitragynine.
7	(MM) $\alpha$ -PPP [ $\alpha$ -pyrrolidinopropiophenone].
8	(NN) $\alpha$ -PVP (desmethylpyrovalerone).
9	(OO) AM-251.
10	(PP) AM-1241.
11	(QQ) AM-2201.
12	(RR) AM-2233.
13	(SS) Buphedrone.
14	(TT) Butylone.
15	(UU) CP-47,497-C7.
16	(VV) CP-47,497-C8.
17	(WW) Desoxypipradol.
18	(XX) Ethylone.
19	(YY) Eutylone.
20	(ZZ) Flephedrone.
21	(AAA) JWH-011.
22	(BBB) JWH-020.
23	(CCC) JWH-022.
24	(DDD) JWH-030.
25	(EEE) JWH-182.
26	(FFF) JWH-302.
27	(GGG) MDAI [5,6-methylenedioxy-2-aminoindane].
28	(HHH) Mitragynine.
29	(III) Naphyrone.
30	(JJJ) Pentedrone.
31	(LLL) Pentylone.
32	(MMM) Methoxetamine
33	[2-(3-methoxyphenyl)-2-(ethylamino)- cyclohexanone].
34	(NNN) A796,260 [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-
35	(2,2,3,3-tetramethylcyclopropyl)methanone].
36	(OOO) AB-001 [(1 <i>s</i> ,3 <i>s</i> )-adamantan-1-yl]
37	(1-pentyl-1H-indol-3-yl)methanone] or [1-Pentyl-3-
38	(1-adamantoyl)indole].
39	(PPP) AM-356 [Methanandamide].
40	(QQQ) AM 1248 [1-[(1-methyl-2- piperidinyl) methyl]-
41	1H-indol-3-yl] tricyclo[3.3.1.1 <sup>3,7</sup> ] dec-1-yl-methanone]or
42	[(1-[(N-methylpiperindin-2-yl)



- 1 Methyl]-3-(Adamant-1-oyl)indole].  
 2 (RRR) AM 2233 Azepane isomer [(2-iodophenyl)  
 3 (1-(1-methylazepan-3-yl)-1H-indol-3-yl)methanone].  
 4 (SSS) CB-13 [1-Naphthalenyl [4-(pentyoxy)-  
 5 1-naphthalenyl]methanone].  
 6 (TTT) UR-144 [(1-pentyl-1H-indol-3-yl)  
 7 (2,2,3,3-tetramethylcyclopropyl)-methanone].  
 8 (UUU) URB 597 [(3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-  
 9 cyclohexylcarbamate].  
 10 (VVV) URB602 [[1,1'-biphenyl]-3-yl-carbamic acid,  
 11 cyclohexyl ester].  
 12 (WWW) URB 754 [6-methyl-2-[(4-methylphenyl)  
 13 amino]-1-benzoxazin-4-one].  
 14 (XXX) XLR-11 or 5-fluoro UR-144  
 15 (1-(5-fluoropentyl)-1H-indol-3-yl)  
 16 (2,2,3,3-tetramethylcyclopropyl)methanone].  
 17 (YYY) AKB48 (Other names include:  
 18 N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide;  
 19 1-pentyl-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-1H-indazole-3-  
 20 carboxamide).  
 21 (ZZZ) 25I-NBOMe (Other names include:  
 22 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-  
 23 benzeneethanamine);  
 24 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)  
 25 methyl]ethanamine).  
 26 (AAAA) 2C-C-NBOMe (Other names include: 25C-NBOMe;  
 27 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)  
 28 methyl]ethanamine);  
 29 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)  
 30 phenethylamine).  
 31 (BBBB) 2NE-1 (Other names include: 1-Pentyl-3-  
 32 (1-adamantylamido)indole).  
 33 (CCCC) STS-135 (Other names include:  
 34 N-Adamantyl-1-fluoropentylindole-3-carboxamide  
 35 (1-5-fluoropentyl)-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-1H-  
 36 indole-3-carboxamide).  
 37 (2) Any compound structurally derived from  
 38 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by  
 39 substitution at the nitrogen atom of the indole ring by alkyl,  
 40 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
 41 1-(N-methyl-2-piperidiny)methyl, 2-(4-morpholinyl)ethyl, or  
 42 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-





- 1 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
2 or not further substituted in the indole ring to any extent and  
3 whether or not substituted in the naphthyl ring to any extent.
- 4 (3) Any compound structurally derived from 3-(1-naphthoyl)  
5 pyrrole by substitution at the nitrogen atom of the pyrrole ring by  
6 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,  
7 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
8 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,  
9 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
10 group, whether or not further substituted in the pyrrole ring to any  
11 extent and whether or not substituted in the naphthyl ring to any  
12 extent.
- 13 (4) Any compound structurally derived from  
14 1-(1-naphthylmethyl)indene by substitution at the 3-position of  
15 the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,  
16 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,  
17 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
18 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
19 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
20 or not further substituted in the indene ring to any extent and  
21 whether or not substituted in the naphthyl ring to any extent.
- 22 (5) Any compound structurally derived from 3-phenylacetylindole  
23 by substitution at the nitrogen atom of the indole ring with alkyl,  
24 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
25 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
26 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
27 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
28 or not further substituted in the indole ring to any extent and  
29 whether or not substituted in the phenyl ring to any extent.
- 30 (6) Any compound structurally derived from  
31 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position  
32 of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,  
33 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,  
34 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
35 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
36 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
37 or not substituted in the cyclohexyl ring to any extent.
- 38 (7) Any compound containing a 3-(benzoyl)indole structure with  
39 substitution at the nitrogen atom of the indole ring by alkyl,  
40 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
41 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
42 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-



- 1 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
 2 or not further substituted in the indole ring to any extent and  
 3 whether or not substituted in the phenyl ring to any extent.
- 4 (8) Any compound, except bupropion or a compound listed under  
 5 a different schedule, structurally derived from  
 6 2-aminopropan-1-one by substitution at the 1-position with either  
 7 phenyl, naphthyl, or thiophene ring systems, whether or not the  
 8 compound is further modified:
- 9 (A) by substitution in the ring system to any extent with alkyl,  
 10 alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide  
 11 substituents, whether or not further substituted in the ring  
 12 system by one or more other univalent substituents;
- 13 (B) by substitution at the 3-position with an acyclic alkyl  
 14 substituent;
- 15 (C) by substitution at the 2-amino nitrogen atom with alkyl,  
 16 dialkyl, benzyl, or methoxybenzyl groups; or
- 17 (D) by inclusion of the 2-amino nitrogen atom in a cyclic  
 18 structure.
- 19 (9) Any compound structurally derived from 3-tetramethyl  
 20 cyclopropanoylindole with substitution at the nitrogen atom of the  
 21 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,  
 22 cycloalkylmethyl, cycloalkylethyl,  
 23 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl) ethyl,  
 24 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-  
 25 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
 26 or not further substituted in the indole ring to any extent and  
 27 whether or not substituted in the tetramethylcyclopropyl ring to  
 28 any extent.
- 29 (10) Any compound containing a N-(1-adamantyl)-  
 30 1H-indazole-3-carboxamide structure with substitution at the  
 31 nitrogen atom of the indazole ring by an alkyl, haloalkyl,  
 32 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
 33 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,  
 34 1-(N-methyl-2-pyrrolidinyl) methyl,  
 35 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
 36 group, whether or not further substituted at the nitrogen atom of  
 37 the carboxamide to any extent, whether or not further substituted  
 38 in the indazole ring to any extent, and whether or not further  
 39 substituted on the adamantyl ring system to any extent. An  
 40 example of this structural class includes AKB48.
- 41 (11) Any compound containing a N-(1-adamantyl)-  
 42 1H-indole-3-carboxamide structure with substitution at the



1 nitrogen atom of the indole ring by an alkyl, haloalkyl,  
2 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
3 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,  
4 1 - ( N - m e t h y l - 2 - p y r r o l i d i n y l ) m e t h y l ,  
5 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
6 group, whether or not further substituted at the nitrogen atom of  
7 the carboxamide to any extent, whether or not further substituted  
8 in the indole ring to any extent, and whether or not further  
9 substituted on the adamantyl ring system to any extent. An  
10 example of this structural class includes STS-135.

11 (12) Any compound containing a 3-(1-adamantoyl)indole  
12 structure with substitution at the nitrogen atom of the indole ring  
13 by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,  
14 cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or  
15 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl,  
16 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
17 group, whether or not further substituted on the adamantyl ring  
18 system to any extent. An example of this structural class includes  
19 AM-1248.

20 (13) Any compound determined to be a synthetic drug by rule  
21 adopted under IC 25-26-13-4.1 **and codified at 856 IAC 8**  
22 **(synthetic drugs). The list of synthetic drugs codified at 856**  
23 **IAC 8 may be accessed electronically from the Indiana board**  
24 **of pharmacy's Internet web site.**

25 SECTION 4. An emergency is declared for this act.



COMMITTEE REPORT

Madam President: The Senate Committee on Rules and Legislative Procedure, to which was referred Senate Bill No. 93, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Delete everything after the enacting clause and insert the following:

(SEE TEXT OF BILL)

and when so amended that said bill be reassigned to the Senate Committee on Judiciary.

(Reference is to SB 93 as introduced.)

LONG, Chairperson

---

COMMITTEE REPORT

Madam President: The Senate Committee on Judiciary, to which was referred Senate Bill No. 93, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Page 3, line 6, after "IC 4-22-2-37.1." insert "**A rule adopted under this section must include the date on which the rule expires.**".

Page 3, delete lines 9 through 11, begin a new paragraph and insert: "**(g) An emergency rule adopted by the board under this section expires on the earlier of the following dates:**

- (1) The expiration date described in subsection (e).**
- (2) The date the emergency rule is amended or repealed by a later rule adopted under this section.**

and when so amended that said bill do pass.

(Reference is to SB 93 as printed February 11, 2015.)

STEELE, Chairperson

Committee Vote: Yeas 7, Nays 0.

